Clinical trial
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to…
NCT00433784 · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal, Other · Completed
Key facts
| NCT number | NCT00433784 |
|---|---|
| Title | H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel |
| Official title | Evaluation of the Effect of the H2 Haplotype and CYP3As Polymorphisms on the Antiplatelet Response to Clopidogrel Given Before Elective Percutaneous Coronary Intervention |
| Lead sponsor | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Coronary Artery Disease, Elective Percutaneous Coronary Intervention |
| Intervention type | Drug, Procedure |
| Interventions | Clopidogrel, Blood sampling - platelet aggregation, Blood sampling - genotyping |
| Enrollment | 120 |
| Start date | Sep 1, 2004 |
| Completion | Apr 1, 2006 |
| First posted | Feb 12, 2007 |
| Last update posted | Aug 21, 2012 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: